文献

J-GLOBAL ID：202002216551687202   整理番号：20A2396004

肝細胞癌の予後における新規バイオマーカーとしてのsnoRNA SNORA71Aの同定【JST・京大機械翻訳】

Identification of snoRNA SNORA71A as a Novel Biomarker in Prognosis of Hepatocellular Carcinoma

著者 (69件)： Ding Yuan (Department of Hepatobiliary and Pancreatic Surgery, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310009, China) ,  Ding Yuan (Key Laboratory of Precision Diagnosis and Treatment for Hepatobiliary and Pancreatic Tumor of Zhejiang Province, Hangzhou 310009, China) ,  Ding Yuan (Research Center of Diagnosis and Treatment Technology for Hepatocellular Carcinoma of Zhejiang Province, Hangzhou 310009, China) ,  Ding Yuan (Clinical Medicine Innovation Center of Precision Diagnosis and Treatment for Hepatobiliary and Pancreatic Disease of Zhejiang University, Hangzhou 310009, China) ,  Ding Yuan (Clinical Research Center of Hepatobiliary and Pancreatic Diseases of Zhejiang Province, Hangzhou 310009, China) ,  Sun Zhongquan (Department of Hepatobiliary and Pancreatic Surgery, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310009, China) ,  Sun Zhongquan (Key Laboratory of Precision Diagnosis and Treatment for Hepatobiliary and Pancreatic Tumor of Zhejiang Province, Hangzhou 310009, China) ,  Sun Zhongquan (Research Center of Diagnosis and Treatment Technology for Hepatocellular Carcinoma of Zhejiang Province, Hangzhou 310009, China) ,  Sun Zhongquan (Clinical Medicine Innovation Center of Precision Diagnosis and Treatment for Hepatobiliary and Pancreatic Disease of Zhejiang University, Hangzhou 310009, China) ,  Sun Zhongquan (Clinical Research Center of Hepatobiliary and Pancreatic Diseases of Zhejiang Province, Hangzhou 310009, China) ,  Zhang Sitong (Department of Hepatobiliary and Pancreatic Surgery, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310009, China) ,  Zhang Sitong (Key Laboratory of Precision Diagnosis and Treatment for Hepatobiliary and Pancreatic Tumor of Zhejiang Province, Hangzhou 310009, China) ,  Zhang Sitong (Research Center of Diagnosis and Treatment Technology for Hepatocellular Carcinoma of Zhejiang Province, Hangzhou 310009, China) ,  Zhang Sitong (Clinical Medicine Innovation Center of Precision Diagnosis and Treatment for Hepatobiliary and Pancreatic Disease of Zhejiang University, Hangzhou 310009, China) ,  Zhang Sitong (Clinical Research Center of Hepatobiliary and Pancreatic Diseases of Zhejiang Province, Hangzhou 310009, China) ,  Zhou Liuzhi (Department of Hepatobiliary and Pancreatic Surgery, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310009, China) ,  Zhou Liuzhi (Key Laboratory of Precision Diagnosis and Treatment for Hepatobiliary and Pancreatic Tumor of Zhejiang Province, Hangzhou 310009, China) ,  Zhou Liuzhi (Research Center of Diagnosis and Treatment Technology for Hepatocellular Carcinoma of Zhejiang Province, Hangzhou 310009, China) ,  Zhou Liuzhi (Clinical Medicine Innovation Center of Precision Diagnosis and Treatment for Hepatobiliary and Pancreatic Disease of Zhejiang University, Hangzhou 310009, China) ,  Zhou Liuzhi (Clinical Research Center of Hepatobiliary and Pancreatic Diseases of Zhejiang Province, Hangzhou 310009, China) ,  Xu Qianhui (Department of Hepatobiliary and Pancreatic Surgery, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310009, China) ,  Xu Qianhui (Key Laboratory of Precision Diagnosis and Treatment for Hepatobiliary and Pancreatic Tumor of Zhejiang Province, Hangzhou 310009, China) ,  Xu Qianhui (Research Center of Diagnosis and Treatment Technology for Hepatocellular Carcinoma of Zhejiang Province, Hangzhou 310009, China) ,  Xu Qianhui (Clinical Medicine Innovation Center of Precision Diagnosis and Treatment for Hepatobiliary and Pancreatic Disease of Zhejiang University, Hangzhou 310009, China) ,  Xu Qianhui (Clinical Research Center of Hepatobiliary and Pancreatic Diseases of Zhejiang Province, Hangzhou 310009, China) ,  Zhou Dongkai (Department of Hepatobiliary and Pancreatic Surgery, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310009, China) ,  Zhou Dongkai (Key Laboratory of Precision Diagnosis and Treatment for Hepatobiliary and Pancreatic Tumor of Zhejiang Province, Hangzhou 310009, China) ,  Zhou Dongkai (Research Center of Diagnosis and Treatment Technology for Hepatocellular Carcinoma of Zhejiang Province, Hangzhou 310009, China) ,  Zhou Dongkai (Clinical Medicine Innovation Center of Precision Diagnosis and Treatment for Hepatobiliary and Pancreatic Disease of Zhejiang University, Hangzhou 310009, China) ,  Zhou Dongkai (Clinical Research Center of Hepatobiliary and Pancreatic Diseases of Zhejiang Province, Hangzhou 310009, China) ,  Li Yanjie (Department of Hepatobiliary and Pancreatic Surgery, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310009, China) ,  Li Yanjie (Key Laboratory of Precision Diagnosis and Treatment for Hepatobiliary and Pancreatic Tumor of Zhejiang Province, Hangzhou 310009, China) ,  Li Yanjie (Research Center of Diagnosis and Treatment Technology for Hepatocellular Carcinoma of Zhejiang Province, Hangzhou 310009, China) ,  Li Yanjie (Clinical Medicine Innovation Center of Precision Diagnosis and Treatment for Hepatobiliary and Pancreatic Disease of Zhejiang University, Hangzhou 310009, China) ,  Li Yanjie (Clinical Research Center of Hepatobiliary and Pancreatic Diseases of Zhejiang Province, Hangzhou 310009, China) ,  Han Xin (Department of Hepatobiliary and Pancreatic Surgery, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310009, China) ,  Han Xin (Key Laboratory of Precision Diagnosis and Treatment for Hepatobiliary and Pancreatic Tumor of Zhejiang Province, Hangzhou 310009, China) ,  Han Xin (Research Center of Diagnosis and Treatment Technology for Hepatocellular Carcinoma of Zhejiang Province, Hangzhou 310009, China) ,  Han Xin (Clinical Medicine Innovation Center of Precision Diagnosis and Treatment for Hepatobiliary and Pancreatic Disease of Zhejiang University, Hangzhou 310009, China) ,  Han Xin (Clinical Research Center of Hepatobiliary and Pancreatic Diseases of Zhejiang Province, Hangzhou 310009, China) ,  Xu Hao (Department of Hepatobiliary and Pancreatic Surgery, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310009, China) ,  Xu Hao (Key Laboratory of Precision Diagnosis and Treatment for Hepatobiliary and Pancreatic Tumor of Zhejiang Province, Hangzhou 310009, China) ,  Xu Hao (Research Center of Diagnosis and Treatment Technology for Hepatocellular Carcinoma of Zhejiang Province, Hangzhou 310009, China) ,  Xu Hao (Clinical Medicine Innovation Center of Precision Diagnosis and Treatment for Hepatobiliary and Pancreatic Disease of Zhejiang University, Hangzhou 310009, China) ,  Xu Hao (Clinical Research Center of Hepatobiliary and Pancreatic Diseases of Zhejiang Province, Hangzhou 310009, China) ,  Bai Yang (Department of Hepatobiliary and Pancreatic Surgery, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310009, China) ,  Bai Yang (Key Laboratory of Precision Diagnosis and Treatment for Hepatobiliary and Pancreatic Tumor of Zhejiang Province, Hangzhou 310009, China) ,  Bai Yang (Research Center of Diagnosis and Treatment Technology for Hepatocellular Carcinoma of Zhejiang Province, Hangzhou 310009, China) ,  Bai Yang (Clinical Medicine Innovation Center of Precision Diagnosis and Treatment for Hepatobiliary and Pancreatic Disease of Zhejiang University, Hangzhou 310009, China) ,  Bai Yang (Clinical Research Center of Hepatobiliary and Pancreatic Diseases of Zhejiang Province, Hangzhou 310009, China) ,  Xu Chang (Department of Hepatobiliary and Pancreatic Surgery, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310009, China) ,  Xu Chang (Key Laboratory of Precision Diagnosis and Treatment for Hepatobiliary and Pancreatic Tumor of Zhejiang Province, Hangzhou 310009, China) ,  Xu Chang (Research Center of Diagnosis and Treatment Technology for Hepatocellular Carcinoma of Zhejiang Province, Hangzhou 310009, China) ,  Xu Chang (Clinical Medicine Innovation Center of Precision Diagnosis and Treatment for Hepatobiliary and Pancreatic Disease of Zhejiang University, Hangzhou 310009, China) ,  Xu Chang (Clinical Research Center of Hepatobiliary and Pancreatic Diseases of Zhejiang Province, Hangzhou 310009, China) ,  Ding Hao (Department of Hepatobiliary and Pancreatic Surgery, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310009, China) ,  Ding Hao (Key Laboratory of Precision Diagnosis and Treatment for Hepatobiliary and Pancreatic Tumor of Zhejiang Province, Hangzhou 310009, China) ,  Ding Hao (Research Center of Diagnosis and Treatment Technology for Hepatocellular Carcinoma of Zhejiang Province, Hangzhou 310009, China) ,  Ding Hao (Clinical Medicine Innovation Center of Precision Diagnosis and Treatment for Hepatobiliary and Pancreatic Disease of Zhejiang University, Hangzhou 310009, China) ,  Ding Hao (Clinical Research Center of Hepatobiliary and Pancreatic Diseases of Zhejiang Province, Hangzhou 310009, China) ,  Ge Yao (Key Laboratory of Precision Diagnosis and Treatment for Hepatobiliary and Pancreatic Tumor of Zhejiang Province, Hangzhou 310009, China) ,  Ge Yao (Research Center of Diagnosis and Treatment Technology for Hepatocellular Carcinoma of Zhejiang Province, Hangzhou 310009, China) ,  Ge Yao (Clinical Medicine Innovation Center of Precision Diagnosis and Treatment for Hepatobiliary and Pancreatic Disease of Zhejiang University, Hangzhou 310009, China) ,  Ge Yao (Clinical Research Center of Hepatobiliary and Pancreatic Diseases of Zhejiang Province, Hangzhou 310009, China) ,  Wang Weilin (Department of Hepatobiliary and Pancreatic Surgery, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310009, China) ,  Wang Weilin (Key Laboratory of Precision Diagnosis and Treatment for Hepatobiliary and Pancreatic Tumor of Zhejiang Province, Hangzhou 310009, China) ,  Wang Weilin (Research Center of Diagnosis and Treatment Technology for Hepatocellular Carcinoma of Zhejiang Province, Hangzhou 310009, China) ,  Wang Weilin (Clinical Medicine Innovation Center of Precision Diagnosis and Treatment for Hepatobiliary and Pancreatic Disease of Zhejiang University, Hangzhou 310009, China) ,  Wang Weilin (Clinical Research Center of Hepatobiliary and Pancreatic Diseases of Zhejiang Province, Hangzhou 310009, China)
資料名： Disease Markers  (Disease Markers)
巻： 2020  ページ： Null  発行年： 2020年 
JST資料番号： W1784A  ISSN： 0278-0240  資料種別： 逐次刊行物 (A)
記事区分： 原著論文  発行国： イギリス (GBR)  言語： 英語 (EN)

抄録/ポイント： 背景.小さな核小体RNA(snoRNAs)は,様々な細胞生理学的過程において重要な役割を果たすことが証明されている。最近,snoRNA SNORA71Aの調節異常は,各種の悪性癌の腫瘍形成に関わることが見出されている。しかし,肝細胞癌(HCC)におけるSNORA71Aの新生効果は,ほとんど不明である。本研究では,HCCにおけるSNORA71A発現とその根底にある意義を探索することを目的とした。方法:細胞系と臨床標本におけるSNORA71Aの発現を,定量的リアルタイムPCRで測定した。次に,すべての登録されたHCC患者を,低および高SNORA71A発現サブグループに分割して,次に,それらを,それぞれの統計解析方法によって,臨床的特徴および生存転帰の側面において比較した。結果:SNORA71Aは,SK-HEP-1([数式:原文を参照]),Huh-7([数式:原文を参照]),Hep3B([数式:原文を参照]),および臨床HCC標本([数式:原文を参照])で有意に低下した。SNORA71A発現サブグループ間の臨床的特徴を比較して,低いSNORA71A発現が,大きな腫瘍直径,多発性病変,カプセル浸潤,悪い腫瘍分化およびTNMステージ([数式:原文を参照])と有意に関連することを示した。さらに,より低いSNORA71A発現を有するHCC患者は術後腫瘍再発(中央値:9.5対35.2か月;低対高;[数式:原文を参照])および不良全生存率(中央値:36.8対52.9か月;低対高;[数式:原文を参照])においてより高いリスクを有することを見出した。さらに,SNORA71A発現は,腫瘍フリー([数式:原文を参照];95%CI[0.263~0.770];[数式:原文を参照])および長期生存([数式:原文を参照];95%CI[0.127~0.657];[数式:原文を参照])の独立危険因子として役立った。結論.本研究は,SNORA71AのダウンレギュレーションがHCC患者の臨床評価および予後予測のための新規バイオマーカーとして役立つことを初めて示した。Copyright 2020 Yuan Ding et al. Translated from English into Japanese by JST.【JST・京大機械翻訳】

シソーラス用語： 浸潤 ,  *RNA【核酸】 ,  腫瘍 ,  分化 ,  *予後 ,  *肝細胞癌 ,  ダウンレギュレーション ,  *バイオマーカー ,  危険因子 ,  腫瘤形成
準シソーラス用語： 細胞株 ,  腫瘍再発 ,  予後予測 ,  全生存率 ,  臨床的特徴 , 【Automatic Indexing@JST】

分類 (2件)： 消化器の腫よう  (GH04000D) ,  腫ようの化学・生化学・病理学  (GE02030N)

引用文献 (29件)：

• H. B. el-Serag, K. L. Rudolph, "Hepatocellular carcinoma: epidemiology and molecular carcinogenesis," Gastroenterology, vol. 132, no. 7, pp. 2557-2576, 2007.
• A. G. Singal, H. B. El-Serag, "Hepatocellular carcinoma from epidemiology to prevention: translating knowledge into practice," Clinical Gastroenterology and Hepatology, vol. 13, no. 12, pp. 2140-2151, 2015.
• H. E. Blum, "Hepatocellular carcinoma: therapy and prevention," World Journal of Gastroenterology, vol. 11, no. 47, pp. 7391-7400, 2005.
• A. M. Moon, N. S. Weiss, L. A. Beste, F. Su, S. B. Ho, G. Y. Jin, E. Lowy, K. Berry, G. N. Ioannou, "No association between screening for hepatocellular carcinoma and reduced cancer-related mortality in patients with cirrhosis," Gastroenterology, vol. 155, no. 4, pp. 1128-1139.e6, 2018.
• T. Kiss, "NEW EMBO MEMBER'S REVIEW: Small nucleolar RNA-guided post-transcriptional modification of cellular RNAs," The EMBO Journal, vol. 20, no. 14, pp. 3617-3622, 2001.

タイトルに関連する用語 (5件)： 肝細胞癌 ,  予後 ,  バイオマーカー ,  snoRNA ,  同定